{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:01:51Z","timestamp":1789142511182,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00770-6","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:21:50Z","timestamp":1749741710000},"page":"1569-1587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient Experience of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Qualitative Patient and Clinician Interviews Informing the Development of a Conceptual Model"],"prefix":"10.1007","volume":"14","author":[{"given":"Jeffrey L.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Paireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mayhew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gasalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Tugaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"770_CR1","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","volume":"267","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267:3565\u201377. https:\/\/doi.org\/10.1007\/s00415-020-10026-y.","journal-title":"J Neurol"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2214\/AJR.20.24061","volume":"216","author":"M Shahriari","year":"2021","unstructured":"Shahriari M, Sotirchos ES, Newsome SD, Yousem DM. MOGAD: how it differs from and resembles other neuroinflammatory disorders. Am J Roentgenol. 2021;216:1031\u20139. https:\/\/doi.org\/10.2214\/AJR.20.24061.","journal-title":"Am J Roentgenol"},{"key":"770_CR3","doi-asserted-by":"publisher","first-page":"175628642094513","DOI":"10.1177\/1756286420945135","volume":"13","author":"H Hegen","year":"2020","unstructured":"Hegen H, Reindl M. Recent developments in MOG-IgG associated neurological disorders. Ther Adv Neurol Disord. 2020;13:1756286420945135. https:\/\/doi.org\/10.1177\/1756286420945135.","journal-title":"Ther Adv Neurol Disord"},{"key":"770_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023;22:268\u201382. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8.","journal-title":"Lancet Neurol"},{"key":"770_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","volume":"26","author":"CL de Mol","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020;26:806\u201314. https:\/\/doi.org\/10.1177\/1352458519845112.","journal-title":"Mult Scler"},{"key":"770_CR6","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","volume":"270","author":"A Al-Ani","year":"2023","unstructured":"Al-Ani A, Chen JJ, Costello F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges. J Neurol. 2023;270:4132\u201350. https:\/\/doi.org\/10.1007\/s00415-023-11737-8.","journal-title":"J Neurol"},{"key":"770_CR7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","volume":"91","author":"K O'Connell","year":"2020","unstructured":"O\u2019Connell K, Hamilton-Shield A, Woodhall M, Messina S, Mariano R, Waters P, et al. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry. 2020;91:1126\u20138. https:\/\/doi.org\/10.1136\/jnnp-2020-323158.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"770_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89\u2013102. https:\/\/doi.org\/10.1038\/s41582-018-0112-x.","journal-title":"Nat Rev Neurol"},{"key":"770_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, Dinoto A, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218. https:\/\/doi.org\/10.3389\/fneur.2022.885218.","journal-title":"Front Neurol"},{"key":"770_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga ASS, Fryer JP, Leavitt JA, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020.","journal-title":"Am J Ophthalmol"},{"key":"770_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. 2021;89:30\u201341. https:\/\/doi.org\/10.1002\/ana.25909.","journal-title":"Ann Neurol"},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89:127\u201337. https:\/\/doi.org\/10.1136\/jnnp-2017-316880.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140:3128\u201338. https:\/\/doi.org\/10.1093\/brain\/awx276.","journal-title":"Brain"},{"key":"770_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40120-023-00474-9","volume":"12","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Gould J, Panahloo Z, Thompson E, Lefelar J, Palace J. Patient pathway to diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): findings from a multinational survey of 204 patients. Neurol Ther. 2023;12:1081\u2013101. https:\/\/doi.org\/10.1007\/s40120-023-00474-9.","journal-title":"Neurol Ther"},{"key":"770_CR15","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3389\/fimmu.2018.02753","volume":"9","author":"F Di Pauli","year":"2018","unstructured":"Di Pauli F, Berger T. Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders? Front Immunol. 2018;9:2753. https:\/\/doi.org\/10.3389\/fimmu.2018.02753.","journal-title":"Front Immunol"},{"key":"770_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1316","volume":"10","author":"JA Lopez","year":"2021","unstructured":"Lopez JA, Denkova M, Ramanathan S, Dale RC, Brilot F. Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. Clin Transl Immunol. 2021;10:e1316. https:\/\/doi.org\/10.1002\/cti2.1316.","journal-title":"Clin Transl Immunol"},{"key":"770_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ncl.2023.06.009","volume":"42","author":"L Cacciaguerra","year":"2024","unstructured":"Cacciaguerra L, Flanagan EP. Updates in NMOSD and MOGAD diagnosis and treatment: a tale of two central nervous system autoimmune inflammatory disorders. Neurol Clin. 2024;42:77\u2013114. https:\/\/doi.org\/10.1016\/j.ncl.2023.06.009.","journal-title":"Neurol Clin"},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","volume":"20","author":"S Fan","year":"2018","unstructured":"Fan S, Xu Y, Ren H, Guan H, Feng F, Gao X, et al. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Mult Scler Relat Disord. 2018;20:144\u201352. https:\/\/doi.org\/10.1016\/j.msard.2018.01.007.","journal-title":"Mult Scler Relat Disord"},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10072-020-04942-0","volume":"42","author":"D Nan","year":"2021","unstructured":"Nan D, Zhang Y, Han J, Jin T. Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis: a case report and review of the literature. Neurol Sci. 2021;42:847\u201355. https:\/\/doi.org\/10.1007\/s10072-020-04942-0.","journal-title":"Neurol Sci"},{"key":"770_CR20","unstructured":"Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, Food and Drug Administration staff, and other stakeholders. Silver Spring, MD: Center for Drug Evaluation and Research. 2020."},{"key":"770_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.820335","volume":"8","author":"O Chisholm","year":"2021","unstructured":"Chisholm O, Sharry P, Phillips L. Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities. Front Med (Lausanne). 2021;8:820335. https:\/\/doi.org\/10.3389\/fmed.2021.820335.","journal-title":"Front Med (Lausanne)"},{"key":"770_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s41669-022-00376-w","volume":"7","author":"RB McQueen","year":"2023","unstructured":"McQueen RB, Mendola ND, Jakab I, Bennett J, Nair KV, Nemeth B, et al. Framework for patient experience value elements in rare disease: a case study demonstrating the applicability of combined qualitative and quantitative methods. Pharmacoecon Open. 2023;7:217\u201328. https:\/\/doi.org\/10.1007\/s41669-022-00376-w.","journal-title":"Pharmacoecon Open"},{"key":"770_CR23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12325-019-00920-x","volume":"36","author":"MG Contesse","year":"2019","unstructured":"Contesse MG, Valentine JE, Wall TE, Leffler MG. The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overview. Adv Ther. 2019;36:997\u20131010. https:\/\/doi.org\/10.1007\/s12325-019-00920-x.","journal-title":"Adv Ther"},{"key":"770_CR24","doi-asserted-by":"publisher","first-page":"1197529","DOI":"10.3389\/fmed.2023.1197529","volume":"10","author":"AS Michel","year":"2023","unstructured":"Michel AS, Kamudoni P, Marrel A, Adiutori R, Desvignes-Gleizes C, Lanar S, et al. Integrating qualitative interviews in drug development and the use of qualitative evidence in product labelling and health technology assessments: a review. Front Med (Lausanne). 2023;10:1197529. https:\/\/doi.org\/10.3389\/fmed.2023.1197529.","journal-title":"Front Med (Lausanne)"},{"key":"770_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"key":"770_CR26","doi-asserted-by":"publisher","unstructured":"Naeem M, Ozuem W, Howell K, Ranfagni S. A step-by-step process of thematic analysis to develop a conceptual model in qualitative research. Int J Qual Methods. 2023. https:\/\/doi.org\/10.1177\/16094069231205789.","DOI":"10.1177\/16094069231205789"},{"key":"770_CR27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25:1229\u201345. https:\/\/doi.org\/10.1080\/08870440903194015.","journal-title":"Psychol Health"},{"key":"770_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS ONE. 2020;15:e0232076. https:\/\/doi.org\/10.1371\/journal.pone.0232076.","journal-title":"PLoS ONE"},{"key":"770_CR29","doi-asserted-by":"publisher","unstructured":"Lamoureux RE, Shields A, Stokes J, Yaworsky A, Galipeau N. How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies. Value Health. 2015. https:\/\/doi.org\/10.1016\/j.jval.2015.03.198.","DOI":"10.1016\/j.jval.2015.03.198"},{"key":"770_CR30","unstructured":"ATLAS.ti. 22.2.5 ed: ATLAS.ti, ATLAS.ti Scientific Software Development GmbH, Berlin, Germany."},{"key":"770_CR31","unstructured":"Kelle U. \"Emergence\" vs. \"Forcing\" of empirical data? A crucial problem of \"Grounded Theory\" reconsidered. Historical Social Research \/ Historische Sozialforschung Supplement. 2007:133\u201356."},{"key":"770_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1017\/cjn.2021.28","volume":"48","author":"JD Krett","year":"2021","unstructured":"Krett JD, Jarvis SE, Alikhani K. Myelin oligodendrocyte glycoprotein antibody-associated myelitis presenting with headache. Can J Neurol Sci. 2021;48:879\u201381. https:\/\/doi.org\/10.1017\/cjn.2021.28.","journal-title":"Can J Neurol Sci"},{"key":"770_CR33","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/ene.14729","volume":"28","author":"S Asseyer","year":"2021","unstructured":"Asseyer S, Henke E, Trebst C, Hummert MW, Wildemann B, Jarius S, et al. Pain, depression, and quality of life in adults with MOG-antibody-associated disease. Eur J Neurol. 2021;28:1645\u201358. https:\/\/doi.org\/10.1111\/ene.14729.","journal-title":"Eur J Neurol"},{"key":"770_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fneur.2020.00778","volume":"11","author":"S Asseyer","year":"2020","unstructured":"Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies. Front Neurol. 2020;11:778. https:\/\/doi.org\/10.3389\/fneur.2020.00778.","journal-title":"Front Neurol"},{"key":"770_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577143","volume":"340","author":"R Pedapati","year":"2020","unstructured":"Pedapati R, Bhatia R, Singh N, Bali P, Gupta P, Saxena R, et al. Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum\u2014a north Indian tertiary care centre experience and review of literature. J Neuroimmunol. 2020;340: 577143. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577143.","journal-title":"J Neuroimmunol"},{"key":"770_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ijms22010100","volume":"22","author":"W Ambrosius","year":"2021","unstructured":"Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci. 2021;22:100. https:\/\/doi.org\/10.3390\/ijms22010100.","journal-title":"Int J Mol Sci"},{"key":"770_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101965","volume":"40","author":"S Asseyer","year":"2020","unstructured":"Asseyer S, Hamblin J, Messina S, Mariano R, Siebert N, Everett R, et al. Prodromal headache in MOG-antibody positive optic neuritis. Mult Scler Relat Disord. 2020;40:101965. https:\/\/doi.org\/10.1016\/j.msard.2020.101965.","journal-title":"Mult Scler Relat Disord"},{"key":"770_CR38","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1055\/s-0043-1777002","volume":"81","author":"K Messias","year":"2023","unstructured":"Messias K, Moreto R, Cruz CA, Ronchi NR, Santos ACD, Messias A, et al. Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience. Arq Neuropsiquiatr. 2023;81:980\u20138. https:\/\/doi.org\/10.1055\/s-0043-1777002.","journal-title":"Arq Neuropsiquiatr"},{"key":"770_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200214","volume":"11","author":"N Tisavipat","year":"2024","unstructured":"Tisavipat N, Stiebel-Kalish H, Palevski D, Bialer OY, Moss HE, Chaitanuwong P, et al. Acute optic neuropathy in older adults: differentiating between MOGAD optic neuritis and nonarteritic anterior ischemic optic neuropathy. Neurol Neuroimmunol Neuroinflamm. 2024;11:e200214. https:\/\/doi.org\/10.1212\/NXI.0000000000200214.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"770_CR40","doi-asserted-by":"publisher","first-page":"205521731879668","DOI":"10.1177\/2055217318796684","volume":"4","author":"S Asseyer","year":"2018","unstructured":"Asseyer S, Schmidt F, Chien C, Scheel M, Ruprecht K, Bellmann-Strobl J, et al. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2018;4:2055217318796684. https:\/\/doi.org\/10.1177\/2055217318796684.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"770_CR41","doi-asserted-by":"publisher","first-page":"205521732211312","DOI":"10.1177\/20552173221131235","volume":"8","author":"DC Ladakis","year":"2022","unstructured":"Ladakis DC, Gould J, Khazen JM, Lefelar JM, Tarpey S, Bies CJ, et al. Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease. Mult Scler J Exp Transl Clin. 2022;8:20552173221131235. https:\/\/doi.org\/10.1177\/20552173221131235.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"770_CR42","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/acn3.52021","volume":"11","author":"IG Hjerthen","year":"2024","unstructured":"Hjerthen IG, Trapaga Hacker C, Meador W, Obeidat AZ, Horta L, Mateen FJ. Impact of neuromyelitis optica spectrum disorder on employment and income in the United States. Ann Clin Transl Neurol. 2024;11:1011\u201320. https:\/\/doi.org\/10.1002\/acn3.52021.","journal-title":"Ann Clin Transl Neurol"},{"key":"770_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1466","volume":"9","author":"T Biernacki","year":"2019","unstructured":"Biernacki T, Sandi D, Kincses ZT, Fuvesi J, Rozsa C, Matyas K, et al. Contributing factors to health-related quality of life in multiple sclerosis. Brain Behav. 2019;9:e01466. https:\/\/doi.org\/10.1002\/brb3.1466.","journal-title":"Brain Behav"},{"key":"770_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","volume":"17","author":"S Eaneff","year":"2017","unstructured":"Eaneff S, Wang V, Hanger M, Levy M, Mealy MA, Brandt AU, et al. Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017;17:116\u201322. https:\/\/doi.org\/10.1016\/j.msard.2017.07.014.","journal-title":"Mult Scler Relat Disord"},{"key":"770_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117546","volume":"428","author":"K Fujihara","year":"2021","unstructured":"Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, et al. Patient-reported burden of symptoms in neuromyelitis optica: a secondary analysis on pain and quality of life. J Neurol Sci. 2021;428:117546. https:\/\/doi.org\/10.1016\/j.jns.2021.117546.","journal-title":"J Neurol Sci"},{"key":"770_CR46","doi-asserted-by":"publisher","unstructured":"Bernitsas E, Osborne B, Taylor N, Zeng F, Anatchkova M, Kielhorn A. Characterizing the impact of NMOSD on mobility, daily activities, and social activities through patient interviews (P13-5.011). Neurology. 2023;100:3387. https:\/\/doi.org\/10.1212\/WNL.0000000000203233.","DOI":"10.1212\/WNL.0000000000203233"},{"key":"770_CR47","doi-asserted-by":"publisher","first-page":"205521732412746","DOI":"10.1177\/20552173241274605","volume":"10","author":"Y Said","year":"2024","unstructured":"Said Y, Ladakis DC, Lefelar JM, Khazen JM, Gould J, Fitzgerald KC, et al. Quality of life is impaired in myelin oligodendrocyte glycoprotein antibody associated disease. Mult Scler J Exp Transl Clin. 2024;10:20552173241274605. https:\/\/doi.org\/10.1177\/20552173241274605.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"770_CR48","doi-asserted-by":"crossref","unstructured":"Ham A, Hjerthen I, Sudhir A, Pandit L, Reddy Y, Tian D, et al. Employment and its associations in an international cohort of myelin oligodendrocyte glycoprotein antibody disease (P051). In: AAN summer conference; 2024; Atlanta, GA, USA.","DOI":"10.1212\/01.wnl.0001050960.45638.92"},{"key":"770_CR49","unstructured":"Paul F, Zappacosta S, Narduzzi S, Khellaf M, Unsworth M, Trenholm E, et al. The disease burden of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): results from a cross-sectional patient and physician survey (P1053) ECTRIMS; 2024; Copenhagen, Denmark."},{"key":"770_CR50","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1212\/wnl.0000000000200052","volume":"98","author":"MW H\u00fcmmert","year":"2022","unstructured":"H\u00fcmmert MW, Sch\u00f6ppe LM, Bellmann-Strobl J, Siebert N, Paul F, Duchow A, et al. Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody-associated disease: CHANCE(NMO) study. Neurology. 2022;98:e1184\u201396. https:\/\/doi.org\/10.1212\/wnl.0000000000200052.","journal-title":"Neurology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00770-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:18:54Z","timestamp":1757186334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00770-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeffrey L. Bennett has served as a Consultant for Horizon Therapeutics, Genentech, TG Therapeutics, Reistone Bio, Roche, Antigenomycs, Chugai, Mitsubishi Tanabe, EMD Serono, Beigene, Novartis, and ImCyse. He has served on scientific advisory and Data Safety Monitoring boards for Clene Nanomedicine and Roche. He serves on a Speakers Bureau for Alexion and received research support from Novartis and Alexion. Asha Paireddy is an employee of UCB. Charlotte Cox is an employee of Adelphi Values, a health outcomes agency that was commissioned by UCB to conduct the research. Megan Mayhew is an employee of Adelphi Values, a health outcomes agency that was commissioned by UCB to conduct the research. Julia Stein is an employee of Adelphi Values, a health outcomes agency that was commissioned by UCB to conduct the research. Teresa Gasalla is an employee of UCB. B\u00e9atrice Tugaut is an employee and shareholder of UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonization guidelines for Good Clinical Practice, and other current data-protection guidance. Ethical approval was provided by Western Copernicus Group Independent Review Board (IRB #20222224; valid from December 19, 2022 to May 2, 2023). Written informed consent was obtained from each patient and clinician prior to study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}